perifosine has been researched along with Disease Exacerbation in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, R; Liang, S; Liu, D; Wang, X; Xu, H; Xu, Z; Yang, L; Zhang, Z | 1 |
| Chen, B; Cheng, L; Hong, DF; Shen, XD; Xin, Y | 1 |
| Arbuck, SG; Chau, CH; Elsayed, YA; Figg, WD; Headlee, D; Hollingshead, M; Kalnitskiy, M; Melillo, G; Messman, R; Monga, M; Murgo, AJ; Peer, C; Ryan, QC; Sausville, EA; Senderowicz, AM; Shah, A | 1 |
| Fram, NR; Keenan, JD; Margolis, TP; McLeod, SD; Strauss, EC | 1 |
| Cho, DC; Figlin, RA; Flaherty, KT; Hutson, TE; Michaelson, MD; Puzanov, I; Richards, P; Samlowski, W; Somer, B; Sosman, JA; Sportelli, P; Vogelzang, NJ | 1 |
| Arlen, PM; Chen, C; Chung, EJ; Dahut, WL; Daniels, A; Figg, WD; Gulley, J; Jones, E; Lee, MJ; Parnes, HL; Posadas, EM; Sparreboom, A; Steinberg, SM; Trepel, JB; Trout, A; Wright, J | 1 |
| Blackstein, M; Bramwell, V; Dancey, J; Dore, N; Eisenhauer, E; Knowling, M; Matthews, S; Tozer, R | 1 |
| Benson, AB; Levy, DE; Marsh, Rde W; Mitchell, EP; Rocha Lima, CM; Rowland, KM | 1 |
5 trial(s) available for perifosine and Disease Exacerbation
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Area Under Curve; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Phosphorylcholine; Treatment Outcome; Young Adult | 2014 |
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Phosphorylcholine; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Salvage Therapy; Survival Rate; Vascular Endothelial Growth Factor A | 2012 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Humans; Leukapheresis; Male; Middle Aged; Neoplasm Metastasis; Phosphorylcholine; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2005 |
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
Topics: Academies and Institutes; Adult; Aged; Antineoplastic Agents; Canada; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasms; Phosphorylcholine; Sarcoma | 2006 |
A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antiemetics; Child; Disease Progression; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Phosphorylcholine; Survival Analysis | 2007 |
3 other study(ies) available for perifosine and Disease Exacerbation
| Article | Year |
|---|---|
Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Down-Regulation; Eukaryotic Initiation Factor-4E; Female; Gene Expression; Humans; Inhibitory Concentration 50; Lymphatic Metastasis; Male; Middle Aged; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Up-Regulation | 2013 |
Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Knockdown Techniques; Humans; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Random Allocation; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Survival Analysis; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2014 |
Perifosine-related rapidly progressive corneal ring infiltrate.
Topics: Corneal Opacity; Disease Progression; Female; Humans; Keratoplasty, Penetrating; Middle Aged; Phosphorylcholine; Waldenstrom Macroglobulinemia | 2010 |